profit from every $100 of sales.
$0$100
Aclarion
$0.02-8.97% today
-69.0% in 1 year
1-year low $0.021-year high $0.21
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Aclarion sold, what it kept, and what it did with the cash.
Sales went from $60,444 in 2022 to $75,730 in 2025, with -$7.23 million of profit last year.
SalesProfit
AI analysis
An AI analyst reads Aclarion's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| -0 | -0 | -0 | 0 | |
| -6 | -5 | -6 | -7 | |
| -5 | -4 | -6 | -7 | |
| -7 | -5 | -7 | -7 | |
| – | – | – | – | |
| -8.0% | -0.4% | -85.2% | 9.0% | |
| -9,202.5% | -6,468.0% | -12,057.2% | -9,312.5% | |
| -11,694.4% | -6,513.4% | -15,293.8% | -9,551.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3 | 2 | 2 | 14 |
| Cash | 1 | 1 | 0 | 12 |
| Total debt | – | 1 | – | – |
| Total liabilities | 1 | 3 | 1 | 1 |
| 2 | -1 | 1 | 13 | |
| – | – | – | – | |
| -197.4% | -854.7% | -525.9% | -44.5% | |
| -317.6% | 674.6% | -720.9% | -56.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | -4 | -5 | -7 | |
| 0 | 0 | 0 | 0 | |
| -5 | -4 | -6 | -7 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 1 | |
| 1 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.0×
- 22.4×
- –
- 1,689,966.3×
- -40,218,963,678.2%
- -426.9%
- 0.0%
Profitability
- 9.0%
- -9,312.5%
- -9,551.9%
- -9,388.7%
- -45.7%
- -415.9%
- -0.0%
- -0.0%
- -0.0%
- 1,365,098,375.8%
Growth
- +7.8%
- –
- −128,079,726.3%
- –
- +917.6%
Financial health
- -1.7×
- 0.00
- 0.0%
- –
- 14.81
- 14.81
- 0.00
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -1.34 | -1.55 | +13.5% |
| Feb 25, 2026 | -3.60 | -3.60 | +0.0% |
| Nov 12, 2025 | -2.93 | -2.93 | +0.0% |
| Aug 14, 2025 | -2.75 | -2.26 | −21.6% |
| May 15, 2025 | -9.29 | -452.25 | +97.9% |
| Apr 9, 2025 | -1,551.93 | -1,130.63 | −37.3% |
| Nov 14, 2024 | -1,309.85 | -1,401.98 | +6.6% |
| Aug 14, 2024 | -1,362.83 | -1,356.75 | −0.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
79Pass
Philip Fisher
35No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
40No pass
Terry Smith
37No pass
Questions about Aclarion
Is Aclarion a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aclarion AI analysis
What does Aclarion do?
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
Does Aclarion pay a dividend?
No. Aclarion does not pay a dividend at the moment; in 2025 it returned $1.21 million to shareholders by buying back its own shares.
How has Aclarion stock done over the past year?
Down 69.0% over the past twelve months, to $0.02. It traded between $0.02 and $0.21 and is 89.7% below its high.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.